Saturday 17 October 2026
Export MNOV’s income statement to Excel — free account
MediciNova, Inc.
MNOV Healthcare Biotechnology
MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023. In the quarter to June 2026, revenue grew 240.6%, EPS grew 28.6% and free cash flow grew 16.8%, each against the same quarter a year earlier.
1.42
0.03
−2.07%
Follow MNOV
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | — | 0.00 | — | — | — | — | — |
Altman Z-Score |
(4.10) | — | 2.95 | — | 15.27 | — | — | — | — | — |
P/S ratio |
45.60 | — | 7.33 | — | 12.97 | — | — | — | — | — |
P/FCF ratio |
0.00 | — | 6.52 | — | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(18.54) | — | 0.12 | — | 13.31 | — | — | — | — | — |
P/Operating CF |
(31.87) | — | (162.18) | — | (35.79) | — | — | — | — | — |
P/B ratio |
1.55 | — | 1.30 | — | 1.56 | — | — | — | — | — |
Price to Tangible BV |
2.01 | — | 1.53 | — | 1.76 | — | — | — | — | — |
EV/Sales |
23.74 | — | 2.71 | — | 5.86 | — | — | — | — | — |
EV/EBITDA |
0.00 | — | 0.00 | — | 0.00 | — | — | — | — | — |
EV/Operating CF |
(3.41) | — | (4.03) | — | (6.27) | — | — | — | — | — |
EV/FCF |
(3.41) | — | 2.41 | — | (6.23) | — | — | — | — | — |
Quick Ratio |
8.11 | 13.64 | 15.55 | 18.35 | 25.21 | 27.36 | 28.63 | 28.43 | 9.72 | 14.80 |
Current Ratio |
8.16 | 13.88 | 15.61 | 18.51 | 25.42 | 27.67 | 28.86 | 28.63 | 9.83 | 15.15 |
Net Debt/EBITDA |
2.32 | 3.19 | 5.16 | 4.00 | 7.01 | 4.24 | 4.55 | 4.00 | 2.15 | 2.22 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.01 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.82 | 0.96 | 0.87 | 0.92 | 0.93 | 0.78 | 0.71 | 0.62 | 0.62 | 0.60 |
Capex/Depreciation |
(0.14) | (0.03) | (1.05) | 1,122.74 | (1.10) | (1.71) | (0.47) | (0.39) | 0.00 | (5.99) |
Interest Coverage |
— | — | — | (18.07) | (71.14) | (39.25) | (12.22) | (16.58) | 89.53 | 163.39 |
| (25.50%) | (19.24%) | (12.93%) | (18.28%) | (13.08%) | (18.95%) | (17.49%) | (26.26%) | (30.51%) | (32.30%) | |
| (23.65%) | (18.09%) | (12.21%) | (17.42%) | (12.45%) | (17.92%) | (16.55%) | (24.33%) | (26.82%) | (27.96%) | |
ROIC |
(77.01%) | (65.23%) | (54.38%) | (77.78%) | (52.14%) | (78.49%) | (78.99%) | (90.25%) | (76.45%) | (65.31%) |
Return on Tangible Assets |
(44.11%) | (28.97%) | (17.88%) | (25.19%) | (14.64%) | (23.65%) | (20.83%) | (24.21%) | (43.76%) | (46.91%) |
Average Days of Receivables |
0.00 | — | 0.00 | — | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
1,746.35% | 0.00% | 565.79% | 0.00% | 211.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
1,503.34% | 0.00% | 524.24% | 0.00% | 141.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.21 | 0.17 | 0.14 | 0.13 | 0.11 | 0.13 | 0.12 | 0.12 | 0.22 | 0.24 |
Share Based Compensation of Revenue |
202.37% | 0.00% | 71.07% | 0.00% | 42.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.42 | — | 0.58 | — | 0.52 | — | — | — | — | — |
Graham Number |
0.00 | — | 0.00 | — | 0.00 | — | — | — | — | — |
Earnings Yield |
(18.32%) | — | (10.59%) | — | (7.75%) | — | — | — | — | — |
Free Cash Flow Yield |
(15.27%) | — | 15.35% | — | (7.25%) | — | — | — | — | — |
Revenue per Share |
0.01 | 0.00 | 0.02 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.20) | (0.22) | (0.15) | (0.26) | (0.19) | (0.24) | (0.21) | (0.22) | (0.20) | (0.20) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.20) | (0.22) | (0.15) | 0.14 | (0.19) | (0.24) | (0.21) | (0.22) | (0.20) | (0.20) |
Cash per Share |
0.63 | 0.82 | 1.04 | 1.19 | 1.47 | 1.35 | 1.48 | 1.52 | 0.80 | 0.73 |
Shareholders Equity per Share |
0.85 | 1.07 | 1.27 | 1.43 | 1.72 | 1.61 | 1.74 | 1.78 | 1.10 | 1.05 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.85 | 1.07 | 1.27 | 1.43 | 1.72 | 1.61 | 1.74 | 1.78 | 1.10 | 1.05 |
Free Cash Flow |
(9.81) | (10.64) | (7.45) | 6.96 | (9.41) | (10.86) | (9.14) | (9.12) | (6.92) | (6.63) |
Working Capital |
27.19 | 38.12 | 47.90 | 55.80 | 69.18 | 58.52 | 62.08 | 60.57 | 25.45 | 23.07 |
Capital Expenditures |
0.00 | 0.00 | (0.02) | 19.87 | (0.03) | (0.04) | (0.01) | (0.01) | — | (0.08) |
Net Current Asset Value |
26.97 | 37.70 | 47.28 | 55.07 | 68.28 | 56.62 | 59.99 | 58.64 | 23.55 | 19.42 |
EV/EBIT |
0.00 | — | 0.00 | — | 0.00 | — | — | — | — | — |
Capex to Sales |
0.01 | 0.00 | 0.02 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Price to Operating Income |
0.00 | — | 0.00 | — | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.42 | 0.83 | 0.44 | 0.39 | 0.45 | 0.38 | 0.59 | 0.49 | 0.45 | 0.16 |
Cash ROIC |
(13.56%) | (11.46%) | (6.57%) | 5.41% | (6.07%) | (8.27%) | (6.59%) | (6.74%) | (10.39%) | (11.31%) |
Accounts Receivable Turnover |
0.00 | — | 0.00 | — | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.44 | 0.00 | 0.00 | 0.51 | 0.00 | 0.04 | 0.04 | 0.02 | 0.03 | 0.05 |
Inventory Turnover |
0.00 | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
602.55 | 0.00 | 0.00 | 729.66 | 0.00 | 10,566.15 | 6,892.24 | 8,692.36 | 19,746.37 | 9,508.12 |
Days of Inventory on Hand |
0.00 | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.86 | 1.05 | 0.71 | 0.41 | 0.51 | 0.53 | 0.53 | 1.07 | 0.94 | 0.27 |
Average Assets |
50.74 | 61.07 | 70.21 | 80.78 | 81.41 | 77.31 | 78.21 | 60.32 | 41.62 | 38.86 |
Average Common Equity |
47.05 | 57.44 | 66.31 | 76.96 | 77.50 | 73.11 | 74.00 | 55.87 | 36.59 | 33.64 |
Columns are period end dates